Dunhill Financial’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Dunhill Financial’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-62	Closed	-$2.41K	–	1017
2025 Q1	$2.41K	Buy	+62	New	+$723	﹤0.01%	705

Other funds holding CNCR

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Dunhill Financial's CNCR Position: Q2 2025 in Review

Dunhill Financial sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2025, closing a stake of 62 shares — an estimated $2.41K sold.

Dunhill Financial first reported a position in CNCR in Q1 2025 and held it in 1 quarter. The position peaked at $2.41K in Q1 2025. 1 fund tracked by Wall St. Rank holds CNCR as of Q2 2025.

Dunhill Financial reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2025 after selling out during the quarter.
Dunhill Financial sold 62 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2025, an estimated $2.41K.
Dunhill Financial first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2025 and held it in 1 quarter.
Dunhill Financial's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $2.41K in Q1 2025.
1 fund tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2025.

Based on Dunhill Financial's 13F filing for Q2 2025, filed 5 Aug 2025.